Table 2.
Resistance allele frequencies in the in vivo drug efficacy study in the North Atlantic Autonomous Region, Nicaragua, 2005–2006*
| Gene (key positions) | Alleles | Municipality | Total, no. (%) | |
|---|---|---|---|---|
| Siuna, no. (%) | Rosita, no. (%) | |||
| pfcrt | CVMNK† | 35 (97.2) | 16 (94.1) | 51 (96.2) |
| (72, 73, 74, 75, 76) | CVIET | 1 (2.8) | 1 (5.9) | 2 (3.8) |
| Total | 36 | 17 | 53 | |
| pdhfr | CNCSI† | 33 (94.3) | 17 (100) | 50 (96.2) |
| (50, 51, 59, 108, 164) | CNCNI | 1 (2.85) | 0 (0) | 1 (1.9) |
| CIRNI | 1 (2.85) | 0 (0) | 1 (1.9) | |
| Total | 35 | 17 | 52 | |
| pdhps | SAKAA† | 35 (97.2) | 13 (100) | 48 (97.9) |
| (436, 437, 540, 581, 613) | SGKAA | 1 (2.8) | 0 (0) | 1 (2.1) |
| Total | 36 | 13 | 49 | |
*
Alleles are described by amino acids in key positions for each gene. Amino acid changes indicating polymorphism are underlined. pfcrt = Plasmodium falciparum chloroquine resistance transporter; pdhfr = P. falciparum dihydrofolate reductase; pdhps = P. falciparum dihydropteroate synthase.
†
Denotes wild-type allele.